|1.||Kantarjian, Hagop: 6 articles (04/2015 - 06/2013)|
|2.||O'Brien, Susan: 6 articles (04/2015 - 06/2013)|
|3.||Thomas, Deborah: 6 articles (04/2015 - 06/2013)|
|4.||Damle, Nitin K: 5 articles (04/2011 - 03/2004)|
|5.||Jabbour, Elias: 4 articles (10/2015 - 08/2013)|
|6.||Dougher, Maureen M: 4 articles (04/2011 - 03/2004)|
|7.||DiJoseph, John F: 4 articles (04/2011 - 03/2004)|
|8.||Ravandi, Farhad: 3 articles (03/2015 - 06/2013)|
|9.||Rytting, Michael: 3 articles (03/2015 - 08/2013)|
|10.||Vandendries, Erik: 3 articles (02/2013 - 04/2010)|
|1.||Non-Hodgkin Lymphoma (Lymphosarcoma)
04/20/2010 - "This was a phase I study to determine the maximum-tolerated dose (MTD), safety, and preliminary efficacy of inotuzumab ozogamicin in an expanded MTD cohort of patients with relapsed or refractory CD22(+) B-cell non-Hodgkin's lymphoma (NHL). "
01/01/2014 - "Inotuzumab ozogamicin has shown promising single-agent activity in patients with ALL and in CD22 positive non-Hodgkin lymphoma. "
10/15/2011 - "Inotuzumab ozogamicin has shown remarkable clinical activity in relapsed/refractory B-cell non-Hodgkin lymphoma, and it has started phase III evaluation. "
09/01/2004 - "A similar conjugate, inotuzumab ozogamicin, is being evaluated at present in Phase I clinical trials in patients with non-Hodgkin's lymphoma. "
05/01/2012 - "This phase I study assessed the tolerability, safety, pharmacokinetics, and preliminary efficacy of inotuzumab ozogamicin administered intravenously in combination with rituximab in Japanese patients with relapsed or refractory B-cell non-Hodgkin lymphoma. "
|2.||B-Cell Lymphoma (Lymphoma, B Cell)
12/15/2004 - "This study evaluated antitumor efficacy of CMC-544 against systemically disseminated B-cell lymphoma. "
12/15/2004 - "When given up to 15 days after B-cell lymphoma dissemination, CMC-544 extended survival of the diseased mice to >100 days, and these mice were considered cured. "
03/01/2004 - "CMC-544, but not unconjugated G5/44, exerted potent cytotoxicity against CD22+ B-cell lymphoma (BCL) cell lines (inhibitory concentration of 50%: 6-600 pM CalichDMH). "
12/15/2004 - "Consistent with its efficacy against the disseminated B-cell lymphoma, CMC-544 also caused regression of established Ramos B-cell lymphoma xenografts in scid mice. "
12/15/2004 - "CMC-544 confers strong therapeutic activity against systemic disseminated B-cell lymphoma and protects mice from hind-limb paralysis and death. "
|3.||Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
02/01/2012 - "We investigated whether the newly developed antibody (Ab) -targeted therapy inotuzumab ozogamicin (CMC-544), consisting of a humanized CD22 Ab linked to calicheamicin, is effective in pediatric primary B-cell precursor acute lymphoblastic leukemia (BCP-ALL) cells in vitro, and analyzed which parameters determine its efficacy. "
10/01/2015 - "Inotuzumab ozogamicin is currently being tested in phase III clinical trials in acute lymphocytic leukemia (ALL). "
08/01/2013 - "Phase II studies of inotuzumab ozogamicin, an ADC which combines anti-CD22 mAb with calicheamicin, an enediyne antibiotic which mediates apoptosis, in patients with acute lymphoblastic leukemia have produced an overall response rate (ORR) of greater than 50 % in treatment-refractory patients. "
11/01/2007 - "This preclinical study investigated antitumor activity of CMC-544 against CD22+ acute lymphoblastic leukemia (ALL). "
10/01/2015 - "The clinical potential of inotuzumab ozogamicin in relapsed and refractory acute lymphocytic leukemia."
04/01/2011 - "Tumor growth inhibition by CMC-544 (>100 days) lasted longer than that by CHOP or CVP. "
04/01/2011 - "Here, we describe anti-tumor efficacy of CMC-544, CHOP or CVP against human BCL xenografts. "
11/01/2007 - "When administered to nude mice with established sc xenografts of REH ALL, CMC-544 caused dose-dependent inhibition of xenograft growth producing complete tumor regression and cures in tumor-bearing mice at the highest dose of 160 microg/kg of conjugated calicheamicin. "
03/01/2004 - "CMC-544 prevented the establishment of BCL xenografts and also caused regression of large BCLs (> 1.5 g tumor mass). "
10/01/2015 - "Promising anti-tumor responses were observed in early stage clinical trials, where inotuzumab ozogamicin was administered either as single agent or in combination with Rituximab. "
|5.||Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell)
10/01/2015 - "This study evaluated the safety and efficacy of inotuzumab ozogamicin (INO), a targeted humanized anti-CD22 antibody conjugated to calicheamicin, plus rituximab (R-INO) every 3 weeks, up to six cycles, followed by high dose therapy and autologous stem cell transplant (HDT-aSCT) in patients with high-risk relapsed/refractory diffuse large B-cell lymphoma (DLBCL). "
10/01/2015 - "A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma."
|3.||CMC544 (Inotuzumab Ozogamicin)
|4.||hLL2 agent (epratuzumab)
|1.||Heterologous Transplantation (Xenotransplantation)
|3.||Drug Therapy (Chemotherapy)